The Safety and Effectiveness of Apixaban in Patients with End-Stage Kidney Disease on Dialysis: A Retrospective Observational Study

Wasim S. El Nekidy, Emna Abidi, Said Abdallah Nabil, Saba Kendakji, Moatasem Ali, Salahdein Aburuz, Bassam Atallah, Fadi Hijazi, Jihad Mallat, Amal AkourJournal of Clinical Medicine 2024 · DOI

TL;DR

This study investigated the safety and effectiveness of apixaban in patients with end-stage kidney disease (ESKD) on dialysis. It found that while apixaban was effective in preventing VTE and stroke, the risk of bleeding was significant, with lower Body Mass Index (BMI) being a key independent risk factor.

What Problem Does This Paper Address?

Patients with end-stage kidney disease (ESKD) who require dialysis are at a higher risk for both blood clots (like VTE and stroke) and bleeding complications. Direct oral anticoagulants (DOACs), such as apixaban, are increasingly used for stroke prevention in non-valvular atrial fibrillation (NVAF) and for VTE treatment. However, the safety and effectiveness of apixaban in the ESKD population on dialysis are not fully established. This is particularly challenging because these patients often have co-existing conditions that can affect drug metabolism and increase bleeding risk. The study aims to fill this knowledge gap by evaluating apixaban's outcomes in this specific, vulnerable patient group.

Methods

This study employed a retrospective observational design. Researchers analyzed data from adult patients with ESKD undergoing intermittent hemodialysis who were prescribed apixaban. Data was collected from an outpatient pharmacy between May 2015 and March 2022. The study collected demographic information, reasons for apixaban prescription, dose appropriateness, use of other antiplatelet medications, and co-existing medical conditions. Crucially, they also tracked bleeding events and thromboembolic events (like VTE and stroke). Statistical analysis included descriptive statistics, Mann-Whitney U tests for comparisons, and multivariate logistic regression to identify independent risk factors for bleeding.

Datasets

The study utilized data from patients treated at a quaternary care hospital's outpatient pharmacy. No new datasets were introduced, and no external benchmarks were used for comparison beyond existing literature.

Key Insights and Ideas

  • BMI as a Bleeding Predictor: The most striking finding is that lower BMI, not just weight, emerged as a significant independent risk factor for bleeding in this ESKD dialysis population. This suggests that body composition, rather than just overall mass, plays a critical role in bleeding risk with apixaban.
  • Apixaban's Dual Role: Apixaban demonstrated effectiveness in preventing VTE and stroke, indicating its therapeutic utility in this high-risk group.
  • Bleeding Risk is Real: Despite its effectiveness, the study highlights that the risk of bleeding, both major and minor, is substantial in ESKD patients on dialysis treated with apixaban.
  • Dosing Nuances: While appropriate dosing was observed in a majority of patients, the study found that daily dose and weight were not significant predictors of bleeding events, further emphasizing the unique role of BMI.

Key Results

  • Patient Cohort: 66 patients with ESKD on dialysis were included.
  • Demographics: Median age was 71 years, and median BMI was 28.2 kg/m².
  • Adherence and Dosing: High medication adherence (84.8%) and appropriate apixaban dosing (62.1%) were noted.
  • Bleeding Events: Major bleeding occurred in 15.2% of patients, and minor bleeding in 36.4%.
  • Thromboembolic Events: VTE and stroke events occurred in 4.5% of cases.
  • Mortality: The all-cause mortality rate was a significant 34.8%.
  • BMI and Bleeding: Multivariate analysis identified BMI as the main independent risk factor for bleeding (OR = 0.9, 95% CI: 0.8–0.99; p = 0.023), indicating that lower BMI is associated with a higher bleeding risk.
  • Other Factors: Age and apixaban daily dose were not significant predictors of bleeding.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: This design can introduce bias and confounding factors.
  • Small Sample Size: The study included only 66 patients, which limits the generalizability of the findings.
  • Lack of Comparative Arm: The study did not include a direct comparison group (e.g., warfarin-treated patients), making it difficult to definitively compare apixaban's outcomes against other anticoagulants.

The authors strongly recommend a larger, prospective study to confirm these findings. They also suggest that future research should explore the role of DOACs in mitigating arteriovenous fistula thrombosis, a critical issue for hemodialysis patients. Additionally, they note the importance of considering risk assessment scores like HAS-BLED, though its utility in hemodialysis patients requires further elucidation.

Summary updated

Abstract

<b>Background:</b> Apixaban has been increasingly utilized for various FDA-approved indications, including stroke prevention and venous thromboembolism (VTE) treatment in patients with end stage kidney disease (ESKD) on hemodialysis. However, the safety and efficacy of its use in this population is not well established. Hence, the purpose of this study is to evaluate the safety and effectiveness of apixaban by examining outcomes in this population. <b>Methods:</b> This was a retrospective observational study that involved adults with ESKD who were on hemodialysis and prescribed apixaban from our hospital's outpatient pharmacy between 1 May 2015, and 31 March 2022. Demographics, apixaban indications, dose appropriateness, concomitant antiplatelet use, and comorbidities data were collected. Bleeding and thromboembolic events were also collected. <b>Results:</b> Sixty-six patients fulfilled the inclusion criteria, 50% of them males. Median age was 71 (63.5-82) years, and the median BMI 28.2 (59.5-86.25) kg/m<sup>2</sup>. The median follow-up time was 5 (1.9-12.3) months. Concomitant antiplatelet use (39.4%) and high medication adherence (84.8%) were observed. During follow-up, major bleeding events occurred in 15.2% of cases, with minor bleeding being more common (36.4%), and VTE and stroke events occurred in 4.5% of cases; appropriate dosing was prevalent (62.1%), and there was an overall all-cause mortality rate of 34.8%. Most patients received a 2.5 mg BID apixaban dose (56.1%), including both NVAF and VTE groups. Notably, the multivariate logistic regression analysis indicated that weight, and daily dose were insignificant predictors of bleeding events (<i>p</i> = 0.104, 0.591), however, the BMI was the main independent risk factor for bleeding in this population [OR = 0.9, 95% CI: 0.8-0.99; <i>p</i> = 0.023]. <b>Conclusions:</b> Our analysis of apixaban-treated ESKD patients highlights that the risk of bleeding is significant, and BMI was the main independent risk factor. A larger prospective study is needed to confirm our findings.
BibTeX
@article{nekidy2024safety,
  author = {Wasim S. El Nekidy and Emna Abidi and Said Abdallah Nabil and Saba Kendakji and Moatasem Ali and Salahdein Aburuz and Bassam Atallah and Fadi Hijazi and Jihad Mallat and Amal Akour},
  title = {{The Safety and Effectiveness of Apixaban in Patients with End-Stage Kidney Disease on Dialysis: A Retrospective Observational Study}},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  doi = {10.3390/jcm13051351},
}
Figure